Press releases

Eysins, Switzerland, 3 April 2025 – Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) microarray. The MosaiQ AiPlex CTDplus multiplex assay, which received

Eysins, Switzerland, February 10th 2025 – AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Celiac Disease (CD) microarray. The MosaiQ AiPlex CD multiplex assay, which received IVDR-CE mark

Eysins, Switzerland February 3rd, 2025 – AliveDx announces the receipt of IVDR-CE mark for its MosaiQ AiPlex® CTDplus multiplex assay. The multiplex assay enables a syndromic approach, simplifying laboratory workflow while delivering fast, actionable results to aid clinicians and laboratorians

Eysins, September 3, 2024 At AliveDx, our mission is to empower diagnostic insights, transform patient care, and innovate for life. We are excited and proud to announce AliveDx has received IVDR-CE mark certification for its multiplexed MosaiQ AiPlex™ CD microarray

Eysins Switzerland 29 July 2024 AliveDx, a global in vitro diagnostics company that aims to transform patient care, today announced LumiQ™ – an innovative, automated immunofluorescence assay (IFA) solution. With this portfolio expansion, AliveDx can offer customers a differentiating, turnkey

Eysins, Switzerland, 29 July 2024 AliveDx (“Company”) is proud to announce it has received IVDR CE mark for its groundbreaking microarray immunoassay, designed for the detection of a specific IgE directed to a protein allergen in human serum. This is